Open-Label, Randomized, Multicenter, Phase Ii Trial Designed To Compare The Efficacy Of Captem Combination Versus Folfiri As Second Line Treatment In Patients (Pts) Who Have Progressed On Or After First-Line Oxaliplatin-Containing Chemotherapy For Advanced, Mgmt Methylated, Ras Mutated Colorectal Cancer (Crc)